However, our data, at least for brain tumours, suggests that optimal benefit from CD4 T cells will be achieved by choosing a tumour-expressed antigen, which will ensure antigen-specific restimulation of the CD4 T cells at the tumour site. This evidence concerns the gene CD4 and neoplasm.